Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions of a new and highly effective HIV prevention drug for roughly $40 per year beginning in 2027.

Lenacapavir, developed by Gilead Sciences and approved earlier this year for HIV prevention under the brand name Yeztugo, is a twice-yearly injection that was nearly 100% effective at preventing HIV in large trials.

Some AIDS experts, including activists and doctors, say it could help control the 44-year-long epidemic that still infects 1.3 million people a year, and which the World Health Organization estimates has killed 44 million.

The price tag, which will enable much broader access in low-and middle-income countries, compares with an estimated U.S. price of around $28,000 a year

See Full Page